Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1087300 | 0.81 | NOS3 (0.37) | NPSR1ALDH1A1CYP1A2ALOX15CASP7 | |
| SCHEMBL5608942 | 0.78 | CA1 (0.39) | NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL9839737 | 0.78 | NPSR1 (0.36) | NPSR1ALDH1A1CYP1A2ALOX15CASP7 | |
| SCHEMBL13324501 | 0.78 | ALDH1A1 (0.44) | NPSR1ALDH1A1CYP1A2ALOX15CASP7 | |
| SCHEMBL395976 | 0.77 | KDM4E (0.35) | ALDH1A1HSD17B10 | |
| SCHEMBL5349748 | 0.76 | ALDH1A1 (0.32) | NPSR1ALDH1A1CYP1A2ALOX15CASP7 | |
| SCHEMBL10885406 | 0.74 | ALDH1A1 (0.36) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL5349754 | 0.74 | ALDH1A1 (0.31) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL395861 | 0.74 | TDP2 (0.36) | ALDH1A1CYP1A2 | |
| SCHEMBL5355803 | 0.74 | NPSR1 (0.33) | NPSR1ALDH1A1CYP1A2ALOX15CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | claimed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | claimed |
| EP-1758859-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005118542-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | claimed |
| CN-113387055-B | Film, method for producing film, and bag | 住友化学株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-117425653-A | Method for producing bipyridine derivative, method for producing macrocyclic compound, method for producing metal complex containing macrocyclic compound as ligand, metal complex, electrode for air battery, and air battery | 住友化学株式会社 | 2024-01-19 | — | — | CN | disclosed |
| US-11643533-B2 | Film, method of producing film, and bag | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-05-09 | — | — | US | disclosed |
| CN-112638997-B | Film and packaging container | 住友化学株式会社 | 2023-04-28 | — | — | CN | disclosed |
| WO-2022249992-A1 | PRODUCTION METHOD FOR BIPYRIDINE DERIVATIVE, PRODUCTION METHOD FOR MACROCYCLIC COMPOUND, PRODUCTION METHOD FOR METAL COMPLEX INCLUDING MACROCYCLIC COMPOUND AS LIGAND, METAL COMPLEX, ELECTRODE FOR AIR BATTERY, AND AIR BATTERY | 住友化学株式会社 | 2022-12-01 | — | — | WO | disclosed |
| CN-110352213-B | Film | 住友化学株式会社 | 2022-09-09 | — | — | CN | disclosed |
| US-11149102-B2 | Film | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20210284829-A1 | FILM, METHOD OF PRODUCING FILM, AND BAG | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-0970976-A1 | Copolymer, process for production thereof, and molded article thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-12 | — | — | EP | disclosed |
| EP-0970963-A2 | Transition metal compound, olefin polymerization catalyst component, olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-12 | — | — | EP | disclosed |
| EP-0963990-A1 | PROCESS FOR PRODUCING CYCLOPENTADIENYL METAL SALTS AND PROCESS FOR PRODUCING CYCLOPENTADIENE DERIVATIVES BY UTILIZING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-12-15 | — | — | EP | disclosed |
| US-5965758-A | Method for producing bridged type transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0942010-A1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-15 | — | — | EP | disclosed |
| CN-1205340-A | Propylene coplymer | SUMITOMO CHEMICAL CO (JP) | 1999-01-20 | — | — | CN | disclosed |
| EP-0852230-A1 | TRANSITION METAL COMPLEXES, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMERS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-07-08 | — | — | EP | disclosed |
| EP-0842939-A1 | TRANSITION METAL COMPLEX, PROCESS FOR THE PREPARATION THEREOF, POLYMERIZATION CATALYST FOR OLEFINS CONTAINING THE COMPLEX, AND PROCESS FOR PRODUCING OLEFIN POLYMERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | NPSR1 232/4885ALDH1A1 2897/4885CYP1A2 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.